stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.89%
- EPS
- +27.0%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) Total debt
LivaNova PLC's total debt at the end of fiscal 2025 was $376.7M, down 40.0% from $627.6M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $299.1M. Over the past ten years it has ranged from $122.9M (fiscal 2016) to $655.6M (fiscal 2020); the current reading is higher than 64% of that period. LivaNova PLC ranks 32nd of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $376.7M | (39.99%) |
| FY2024 | $627.6M | 6.98% |
| FY2023 | $586.7M | 8.34% |
| FY2022 | $541.5M | 126.08% |
| FY2021 | $239.5M | (63.47%) |
| FY2020 | $655.6M | 94.13% |
| FY2019 | $337.7M | 100.63% |
| FY2018 | $168.3M | 15.30% |
| FY2017 | $146.0M | 18.82% |
| FY2016 | $122.9M | (29.51%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $299.1M | 1.91% |
| Jun 2026 | $293.5M | 1.98% |
| Mar 2026 | $287.8M | (23.59%) |
| Dec 2025 | $376.7M | (13.31%) |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BRKR Bruker Corporation compare | $1.7B |
| ITGR Integer Holdings Corporation compare | $1.3B |
| BIO Bio-Rad Laboratories, Inc. compare | $1.2B |
| HAE Haemonetics Corporation compare | $1.1B |
| NEOG Neogen Corporation compare | $774.2M |
| IRTC iRhythm Holdings, Inc. compare | $651.9M |
| LIVN LivaNova PLC | $299.1M |
| TXG 10x Genomics compare | $98.0M |
| AXGN AxoGen, Inc. compare | $17.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement